Using Real-World Evidence to Advance Geometric Atrophy Care

Despite advances in treating geometric atrophy (GA), a progressive eye disorder, patient responses to treatment are variable. In a new interview with AJMC, Ashard Khanani, MD, talks about how real-world evidence (RWE) can help advance GA care by revealing the real-world impact of treatments on patient health outcomes.

According to Khanani, “I think the biggest question the field is struggling with is what is efficacy when it comes to a real-world patient. Because, in trials, you saw a certain percent of efficacy, but that’s average. There are patients who benefit a lot from treatment. There are patients who don’t benefit too much from treatment. And because it’s a variable disease with so many factors, as we discussed earlier in this program, it’s a multifactorial disease. It’s very hard to know how good a therapy is working because you would have to take the therapy off to know how that trajectory is looking.”

To read more, click here.

(Source: AJMC, April 28^th, 2023)